Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20092155 | 0.81 | TYK2 (0.45) | TYK2 | |
| SCHEMBL20150151 | 0.75 | ERN1 (0.45) | TYK2CYP19A1MAPT | |
| SCHEMBL20150166 | 0.74 | SIRT6 (0.46) | TYK2ALDH1A1HTTMAPTHPGD | |
| SCHEMBL20225763 | 0.74 | TSHR (0.53) | ALDH1A1CYP19A1KDM4EHTTPOLB | |
| SCHEMBL20150159 | 0.71 | HTT (0.51) | TYK2ALDH1A1CYP19A1HTTPOLB | |
| SCHEMBL29686179 | 0.70 | TSHR (0.50) | ALDH1A1CYP19A1KDM4EHTTPOLB | |
| SCHEMBL3617121 | 0.70 | CYP19A1 (0.50) | ALDH1A1CYP19A1KDM4EHTT | |
| SCHEMBL20150149 | 0.70 | CYP19A1 (0.49) | ALDH1A1CYP19A1KDM4EHTTMAPT | |
| SCHEMBL29739895 | 0.70 | CYP19A1 (0.49) | ALDH1A1CYP19A1KDM4EHTTMAPT | |
| SCHEMBL26118896 | 0.70 | TSHR (0.50) | ALDH1A1CYP19A1KDM4EHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885ALDH1A1 4827/4885CYP19A1 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.